1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAccelerating Research and Development of Next Generation Malaria Vaccines Against Malaria is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Supports basic research and preclinical development of highly efficacious next-generation malaria vaccines. Relevant to university research on malaria parasite biology including egress mechanisms.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
September 2025 DMID Council-Approved Concepts | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.
coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.
Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information September 2025 DMID Council-Approved Concepts Due to current HHS and NIH restructuring, some content on niaid.
nih. gov is not being updated regularly. Please refer to clinicaltrials.
gov and nih. gov for the most up-to-date information on NIH research. Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council’s input.
If NIAID publishes an initiative from one of these concepts, we link to it below. To find NIAID initiatives, go to Explore NIH Grant Opportunities . Note: Council approval does not guarantee that a concept will become an initiative.
Fiscal Year (FY) 2027 Division of Microbiology and Infectious Diseases (DMID) Concepts Infectious Diseases Clinical Trials Network (IDCTN) Clinical Research Network on Antimicrobial Resistance Tuberculosis Research Advancement Centers (TRACs) Coccidioidomycosis Collaborative Research Centers Accelerating Research and Development of Next Generation Vaccines Against Malaria—A Model for Mosquito-Borne Diseases Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases Infectious Diseases Clinical Trials Network (IDCTN) For more information, go to View Grant Opportunity for Infectious Diseases Clinical Trials Network (IDCTN) .
Note: Information is tentative and subject to change. Request for Applications—proposed FY 2027 initiative Objective: The objective of this initiative is to advance clinical and public health outcomes for NIAID scientific priorities in evaluating therapeutics, vaccines, biologics, diagnostics, and devices targeting infectious diseases, including emerging and chronic infections.
This will be promoted by identifying experienced clinical trial sites and teams, engaging investigators and other scientific leaders in the field to solicit and generate innovative concepts for advancing public health, and providing opportunities for new clinical trialists. Description: This initiative will support a clinical trials network to develop clinical trial concepts to address infectious diseases.
The Infectious Diseases Clinical Trials Network (IDCTN) is comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supporting the evaluation of therapeutics, vaccines, biologics, diagnostics, and devices targeting infectious diseases, including emerging and chronic infections.
The CTEUs provide the clinical infrastructure for implementing clinical trials and studies and provide rapid response capabilities to studies of medical countermeasures in response to public health and disease threats.
The NCC, comprised of leaders from the CTEU and in collaboration with NIAID, provides the scientific leadership and organizational framework for a collaborative and integrated network, engages with experts in the field to solicit and generate innovative clinical trial concepts for advancing public health while creating opportunities to advance investigators early in their careers and those new to the field.
The initiative gives NIH the capabilities to rapidly implement clinical trials and studies for public health priorities that address the needs of the U.S. population. Clinical Research Network on Antimicrobial Resistance For more information, go to View Grant Opportunity for Clinical Research Network on Antimicrobial Resistance . Note: Information is tentative and subject to change.
Request for Applications—proposed FY 2027 initiative Objective: To support a Clinical Research Network (CRN) on Antimicrobial Resistance (AMR), which will design, prioritize, implement, and manage a clinical research program to address key clinical questions in AMR. Description: This initiative aims to continue support for a CRN focused on AMR to address critical clinical research questions.
The program will encompass four key components: Scientific Leadership Center, Clinical Operations Center, Laboratory Center, and Statistics and Data Coordination Center. The Scientific Leadership Center will oversee the network’s overarching research agenda on AMR and offer clinical research opportunities for early-stage investigators thereby fostering the next generation of clinical researchers in infectious diseases and AMR.
The general areas of clinical research and activities may include: Clinical evaluation of new interventions, including alternatives such as bacteriophage therapy, monoclonal antibodies, and microbiome, to effectively treat and prevent AMR infections. The research will focus on the AMR priority lists from the CDC, including AMR fungal pathogens.
Strategy trials to optimize the use of currently licensed antibacterials (e.g., dose, duration, clinical algorithms, and combinations) to reduce the risk of resistance. Research to identify biomarkers and develop rapid diagnostic tools for refining treatment strategies and reducing the misuse or overuse of antibiotics, and validate new diagnostic tests to support regulatory submissions.
Clinical utility studies of diagnostic tests to determine their impact on patient and facility-level outcomes and prescribing behavior. Molecular epidemiological studies to provide data on the associations between patient characteristics, clinical outcomes, and resistant genotypes/phenotypes, informing future interventional therapeutics.
Private and public partnerships to foster a robust community, guide optimal clinical trial designs, and enhance robust clinical trials to advance potential therapies in a timely manner. Tuberculosis Research Advancement Centers (TRACs) For the published request for applications, check the May 4, 2026 grant opportunity, Tuberculosis Research Advancement Centers (TRACs) (P30, Clinical Trial Not Allowed) .
Coccidioidomycosis Collaborative Research Centers For the published request for applications, check the May 4, 2026 grant opportunity, Coccidioidomycosis Collaborative Research Centers (P01, Clinical Trial Not Allowed) .
Accelerating Research and Development of Next Generation Vaccines Against Malaria—A Model for Mosquito-Borne Diseases For more information, go to View Grant Opportunity for Accelerating Research and Development of Next Generation Vaccines Against Malaria—A Model for Mosquito-Borne Diseases . Note: Information is tentative and subject to change.
Request for Applications—proposed FY 2027 initiative Objective: The objective of this initiative is to support research and/or preclinical development of highly efficacious malaria vaccines that capitalize on recent vaccine technological innovations, especially encouraging structure-based immunogen design, improved formulations, and combination vaccines.
Description: The overall goal of this initiative is to stimulate basic research, discovery, and/or preclinical development activities to enable and accelerate the generation of highly efficacious malaria vaccines against two major human parasites, Plasmodium falciparum and P.
vivax , and potentially other mosquito-borne illness by encouraging cross-fertilization and collaboration across different scientific disciplines and/or with vaccine developers or product development partners.
The initiative will specifically seek product candidates or concepts targeting pre-erythrocytic, blood, and/or sexual stages of Plasmodium parasites, as well as mosquito vector products to create a highly efficacious and effective vaccine to prevent infection, reduce disease burden, and/or block transmission of malaria and/or other mosquito-borne diseases.
The initiative will emphasize structure-based immunogen design and improvement as well as combination vaccine design and formulation, calling for utilization of recent technological advances in vaccine platforms and other vaccinology innovations.
Regardless of the stage of proposed research and development activities (discovery or preclinical development), proposed vaccine concepts should take into consideration downstream product feasibility aspects such as favorable product features (e.g., easily deployable formulations and straightforward immunization regimens) to address real world implementation demands.
Partnership with product development partnerships or commercial developers is highly encouraged.
Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases Broad Agency Announcement—proposed FY 2027 initiative Objective: To advance the development of candidate medical countermeasure products, platform technologies, and devices from preclinical studies through early-phase clinical trials/validation, thereby building a data set to reduce risk for advanced development and regulatory approval and/or gain efficiencies/speed for future use.
Description: This program supports the preclinical and early clinical development of candidate vaccines, therapeutics, diagnostics, and platform technologies for NIAID priority biodefense and emerging infectious disease pathogens.
Contract funding will support vaccine and therapeutic development through candidate testing, manufacture, preclinical, or nonclinical toxicology testing, and early clinical studies which may include Phase 1 and/or Phase 2 clinical trials. Diagnostics can be most critically supported in the planning, design, development, and verification phases of product development.
This program reduces risk and enables candidate medical countermeasures to transition to other funding to support advanced clinical development (Phase 2b and beyond), large-scale manufacturing, and regulatory approval. Content last reviewed on May 7, 2026
According to the current listing, eligibility includes: Universities, research institutions, and other eligible organizations as per NIH guidelines. Confirm the full requirements in the official notice before applying.
Applications for Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria are due February 11, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article